Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Gupta A, El-Rami H, Barham R, Fleming A, van Hemert J, Sun JK, Silva PS, Aiello LP. Effect of phase-plate adjustment on retinal image sharpness and visible retinal area on ultrawide field imaging. Eye (Lond). 2019 Apr 1;33(4):587-91. doi: 10.1038/s41433-018-0270-5
Dalley C, Basarir H, Wright JG, Fernando M, Pearson D, Ward SE, Thokula P, Krishnankutty A, Wilson G, Dalton A, Talley P, Barnett D, Hughes D, Porter NR, Reilly JT, Snowden JA. Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. J Clin Pathol. 2015 Apr;68(4):292-300. doi: 10.1136/jclinpath-2014-202624
Oldenburg CE, Keenan JD, Cevallos V, Chan MF, Acharya NR, Gaynor BD, McLeod SD, Esterberg EJ, Porco TC, Lietman TM. Microbiological cure times in acanthamoeba keratitis. Eye (Lond). 2011 Sep;25(9):1155-60. doi: 10.1038/eye.2011.126